Q-omics provides the consensus-scored BDH2P1 profile across patient tissues and cancer cell-line models. BDH2P1 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, BDH2P1 is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, BDH2P1 RNA expression shows 11,942 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KIRP, and UVM as cancer lineages where BDH2P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BDH2P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BDH2P1 survival associations across molecular data types. BDH2P1 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BDH2P1 RNA expression–survival associations across cancer types. High BDH2P1 expression shows unfavorable associations in UVM and STAD, but favorable associations in ACC, MESO, KIRC and READ. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for BDH2P1 RNA expression.
This table summarizes BDH2P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for BDH2P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BDH2P1 shows lower tumor expression in KIRP, KIRC, LUSC, KICH, STAD and BRCA. The KIRP box plot shows higher BDH2P1 RNA expression in normal versus tumor tissue (log2 FC = −0.972, t-test p < 0.001).
This table shows molecular features associated with BDH2P1 in patient tissues and cancer cell lines. In patient samples, BDH2P1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
